S

Shattuck Labs
D

STTK

1.01000
USD
-0.10
(-9.01%)
Market Closed
Volume
7,981
EPS
-2
Div Yield
-
P/E
-1
Market Cap
48,204,542
News

Title: Shattuck Labs

Sector: Healthcare
Industry: Biotechnology
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.